The Center for Technology Licensing's (CTL) mission is to bring the University's scientific discoveries, technological innovations, and medical advances to the marketplace for societal benefit and to foster economic development within New York State and across the nation.
Licensing
CTL is industry's link to Cornell's broad range of innovative research that is available for licensing. Over the years, Cornell technologies have been licensed to industry partners all over the world in support of Cornell's land-grant mission and to develop these technologies and plant varieties into products and services for public good.
Available Cornell Technologies
- Single Sperm Sequencing Assay for Prediction of Autism Risk and as a Substitute for Manual Sperm Analysis
- Pumpless, Unidirectional, and Multiorgan Microfluidic Platform for Preclinical Drug Testing
- Ultra-sensitive Detection of Circulating Tumor DNA through Genome-wide Integration
- Systems and Methods for Detection of Residual Disease
- MALT1 inhibitors to treat B cell Lymphomas
- Novel Mitochondrial Calcium Uniporter Blockers
Current Featured Technologies
- » Reversible Small Molecule Immunoproteasome Inhibitors
- » Accommodating Intraocular Lens & Conversion Plate
- » Generic Programmable Tag
- » Biomarkers for Predicting & Diagnosing Cancer/Metastasis
- » Red Wine Grape ‘Arandell’
- » White Wine Grape ‘Aromella’
- » Tethered Enzyme Technology (TET™) Point-of-Care Testing for Brain Injuries